http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20070021171-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2005-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20070021171-A |
| titleOfInvention | 1,3,4-oxadiazol-2-one as PPA delta modulator |
| abstract | The present invention relates to 1,3,4-oxadiazolone, and pharmaceutically acceptable salts thereof, stereoisomers, tautomers or solvates thereof. The compounds of the present invention are modulators of PPAR delta and are therefore particularly useful as a pharmaceutical agent for the treatment of myelin disrupting diseases and for the treatment of fatty acid metabolism and glucose using diseases.n n n 1,3,4-oxadiazolone, PPAR delta modulator, myelin destruction disease, fatty acid metabolism disease, glucose utilization disease |
| priorityDate | 2004-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163726889 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465393714 |
Total number of triples: 16.